ライフサイエンスコーパス: total body irradiation

1 test abnormalities among those who received total body irradiation.

2 ell receptor monoclonal antibody followed by total body irradiation.

3 20 lymphoma in mice preconditioned with 6 Gy total body irradiation.

4 -identical marrow transplantation after 1 Gy total body irradiation.

5 with (131)I-BC8 Ab and fludarabine plus 2 Gy total body irradiation.

6 exhibit enhanced survival following 8-10 Gy total body irradiation.

7 and responded to antigenic stimulation after total body irradiation.

8 tical donors after conditioning with 920 cGy total body irradiation.

9 ation therapy in mice with anemia induced by total body irradiation.

10 ative conditioning with fludarabine and 2 Gy total body irradiation.

11 e marrow after conditioning with 100-300 cGy total body irradiation.

12 these biomarker genes in patients undergoing total body irradiation.

13 conditioning, primarily cyclophosphamide and total body irradiation.

14 e given HSCT after conditioning with 920 cGy total body irradiation.

15 s were conditioned with cyclophosphamide and total body irradiation.

16 ophic skeletal muscle even in the absence of total body irradiation.

17 s on each of 2 consecutive days, followed by total body irradiation.

18 s were conditioned with cyclophosphamide and total body irradiation.

19 ft and a conditioning regimen with > 450 cGy total body irradiation.

20 autologous bone marrow transplantation after total body irradiation.

21 depletion-based conditioning with 1 or 3 Gy total body irradiation.

22 increases survival of mice exposed to lethal total body irradiation.

23 e transplanted after varying doses of cGy of total body irradiation.

24 tion of IL-22 enhanced thymic recovery after total body irradiation.

25 and hematopoietic radioprotection following total body irradiation.

26 ipheral blood compartments of mice post-4 Gy total body irradiation.

27 VCA recipients with 200-, 300-, and 400-cGy total body irradiation.

28 yclophosphamide, fludarabine, and 200 cGy of total body irradiation.

29 occurred within the IFRT site and five after total-body irradiation.

30 ustained engraftment can be achieved without total-body irradiation.

31 olgus monkeys were conditioned with low-dose total body irradiation (1.5 Gy on days -6 and -5), suppl

32 Conditioning therapy involved total body irradiation 2 Gy +/- fludarabine 30 mg/m2.

33 oablative conditioning regimen consisting of total-body irradiation (2 Gy) with or without fludarabin

34 RIC regimens included fludarabine/total body irradiation 200 cGy (n = 5) or 450 cGy (n = 1

35 phamide (50 mg/kg), and a single fraction of total body irradiation (200 cGy) with cyclosporine and m

36 underwent conditioning with a single dose of total-body irradiation (200 cGy).

37 g of alemtuzumab (1 mg/kg in divided doses), total-body irradiation (300 cGy), sirolimus, and infusio

38 Eight recipient dogs received total body irradiation (4.5 cGy), hematopoietic cell tra

39 HDIT included total body irradiation (800 cGy) with lung shielding, cy

40 We found that total body irradiation, a conditioning regimen required

41 Using nonmyeloablative doses of total body irradiation, a short course of immunosuppress

42 ere hypoplastic and more apoptotic 24 h post-total body irradiation, a time when stem cell survival i

43 anti-CD45 and an otherwise inactive dose of total-body irradiation allowed engraftment of H2 fully a

44 men involving anti-CD154 and low dose (3 Gy) total body irradiation, allowing achievement of mixed ch

45 = 498) or unrelated (n = 336) HCT after 2 Gy total body irradiation alone (n = 171) or combined with

46 nstitutions using conditioning with low-dose total body irradiation alone or combined with fludarabin

47 ated donors following conditioning with 2 Gy total body irradiation alone or in combination with flud

48 ne-refractory CLL were conditioned with 2 Gy total-body irradiation alone or combined with fludarabin

49 Our results show that total body irradiation alters intracellular signaling an

50 oietic cells using a combination of low-dose total body irradiation and a short course of immunosuppr

51 n (BMT) following conditioning with low-dose total body irradiation and anti-CD154 antibody.

52 rance are achieved in mice receiving 3 Gy of total body irradiation and anti-CD154 mAb followed by al

53 ents received a single fraction dose of 2 Gy total body irradiation and HC transplants from HLA-ident

54 nfused into 3 adult baboons following lethal total body irradiation and hematopoietic support or with

55 ient Tregs after a conditioning regimen with total body irradiation and led to a TGF-beta-dependent i

56 -ibritumomab tiuxetan, fludarabine, and 2 Gy total body irradiation and matched-related (15) or unrel

57 of pretransplant T cell depletion, low-dose total body irradiation and posttransplant (donor) bone m

58 Total body irradiation and radiation proctitis were moni

59 -Furth rats were conditioned with 950 cGy of total body irradiation and transplanted with ACI bone ma

60 r nonmyeloablative (3 Gy) and minimal (1 Gy) total body irradiation and treatment with costimulation

61 clophosphamide (CY) and busulfan (BU) (67%), total-body irradiation and CY (21%), BU-fludarabine (10%

62 The conditioning regimen included total-body irradiation and cyclophosphamide (n = 3), bus

63 preconditioning or after 200 cGy or 900 cGy total-body irradiation and evaluated after 4 months.

64 etic stem-cell transplantation that includes total-body irradiation and treatment with alemtuzumab an

65 smoking history, conditioning with high-dose total body irradiation, and an absolute lymphocyte count

66 Patient or donor age, total body irradiation, and graft-versus-host disease or

67 globulin, fludarabine, cyclophosphamide, and total body irradiation, and graft-versus-host disease pr

68 nsolidation with myeloablative chemotherapy, total-body irradiation, and ABMT versus three cycles of

69 NOD mice received various combinations of total body irradiation, anti-CD154, anti-CD8alpha, anti-

70 recipients who receive conditioning without total body irradiation are not well known.

71 al cell apoptosis after they were exposed to total body irradiation as compared with TNFR1-deficient

72 13)Bi)-labeled anti-CD45 antibody to replace total body irradiation as conditioning for hematopoietic

73 re enriched early after TLI/ATS + BMT versus total body irradiation/ATS + BMT.

74 X compared with TLI/ATS, lethal or sublethal total body irradiation/ATS/CTX, or CTX/ATS conditioning.

75 s the antileukemic benefits of myeloablative total body irradiation-based conditioning and unrelated

76 cantly higher rate of DC was associated with total body irradiation-based conditioning and with acute

77 critical to the induction of tolerance in a total body irradiation-based model.

78 sed with hematologic malignancies received a total body irradiation-based myeloablative conditioning

79 te deletional tolerance as the mechanism for total body irradiation-based nonmyeloablative conditioni

80 in patients conditioned with a fractionated total body irradiation-based regimen has shown encouragi

81 blastic leukemia 10) were conditioned with a total body irradiation-based regimen.

82 hocytic leukemia patients treated with 12 Gy total body irradiation-based regimens and allogeneic tra

83 ted donor transplantation with myeloablative total body irradiation-based regimens.

84 lymphoma who were considered ineligible for total-body irradiation because of older age or prior rad

85 shed in dogs given a sublethal dose (1-2 Gy) total body irradiation before and a short course of immu

86 ditioning of neonates with 100 to 400 cGy of total body irradiation before normal donor marrow transp

87 mg/kg, fludarabine 200 mg/m2, and 200 cGy of total body irradiation (Bu/Flu/TBI).

88 tumoral proliferation of T-effector cells in total body irradiation-conditioned recipients.

89 The toxicity of total body irradiation conditioning and potential for gr

90 e marrow (BM) cells or through myeloablative total body irradiation conditioning and reconstitution w

91 Furthermore, this procedure usually requires total body irradiation conditioning of recipients.

92 day pulmonary metastases of MCA 205 received total body irradiation conditioning or were nonirradiate

93 eral strain combinations irrespective of the total body irradiation conditioning regime.

94 However, when mice were given more intense total body irradiation conditioning regimens combined wi

95 To reduce or eliminate total body irradiation conditioning regimens, we have so

96 ex vivo antigen stimulation irrespective of total body irradiation conditioning.

97 CD34+ cells can engraft even after low-dose total body irradiation conditioning.

98 Total body irradiation-containing preparative regimen wa

99 When used with cyclophosphamide/total body irradiation (Cy/TBI) conditioning, sirolimus

100 Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are t

101 nditioning regimens of cyclophosphamide plus total body irradiation (CY/TBI), busulfan plus cyclophos

102 ioned with cyclophosphamide and fractionated total-body irradiation (Cy/TBI) or busulfan and cyclopho

103 HDIT consisted of total body irradiation, cyclophosphamide, and antithymoc

104 receptor and anti-CD8 monoclonal antibodies, total body irradiation, cyclosporine A and mycophenolate

105 Although the addition of 600 rad of total body irradiation delayed tumor growth, further ado

106 ll transplantation with cyclophosphamide and total body irradiation develop wide-spectrum manifestati

107 erance, significantly decreasing the minimum total body irradiation dose required.

108 The omission of high-dose total body irradiation, dose adjustments of busulfan to

109 ent regimens:fludarabine-melphalan (n = 46); total body irradiation-etoposide (n = 28), and busulfan-

110 Rabbits exposed to 10 cGy of total body irradiation exhibited T cell deficiency, with

111 eparative regimen of nonmyeloablating (5 Gy) total body irradiation experienced the rapid rejection o

112 ution and toxicity in baboons that underwent total body irradiation followed by autologous transplant

113 ancies conditioned with fludarabine and 2 Gy total body irradiation followed by HLA-matched unrelated

114 in which the marrow recipients received 2 Gy total body irradiation followed by marrow infusions from

115 ated with a nonmyeloablative dose of 200 cGy total body irradiation followed by matched-littermate SC

116 of a specific anti-CD44 mAb (S5) and 200 cGy total body irradiation followed by postgrafting immunosu

117 Total body irradiation followed by transplantation with

118 d MCA-205 tumors were treated with sublethal total body irradiation, followed by adoptive transfer of

119 were uniformly cured after administration of total body irradiation, followed by the transplantation

120 (P=0.01) and, in multivariate analysis, with total body irradiation for all lineages (P<0.01).

121 ne tumor recipients were preconditioned with total body irradiation from 0 to 500 cGy or with a 30-da

122 matched sibling donors received fractionated total body irradiation (FTBI) and high-dose VP16, wherea

123 n consisted of 90 mg/m2 fludarabine and 2 Gy total body irradiation given before and mycophenolate mo

124 ludarabine and targeted busulfan (n = 25) or total body irradiation (>/=12 Gy; n = 18).

125 nner, with the administration of DA prior to total body irradiation having the greatest protective ef

126 ctive regimen consisted of hyperfractionated total body irradiation (HFTBI), thiotepa, and fludarabin

127 T was seen only in patients conditioned with total-body irradiation (HR, 3.9 [95% CI, 2.6-6.8]).

128 losuppressive regimen, consisting of 100 cGy total body irradiation, immunotoxin mediated T-cell depl

129 ry of young BM ECs along with HSCs following total body irradiation improved HSC engraftment and enha

130 Conditioning regimens included total body irradiation in 199 (44%) cases.

131 esus macaques conditioned with myeloablative total body irradiation in the absence or presence of sin

132 Conditioning included total-body irradiation in 92% of patients.

133 unotherapy targeting CD45 may substitute for total-body irradiation in hematopoietic cell transplanta

134 ive preparative regimen that did not involve total-body irradiation in young children with Hurler's s

135 In contrast, no significant increase in total body irradiation-induced apoptosis or tissue injur

136 iation-induced gastrointestinal syndrome and total body irradiation-induced hematopoietic failure.

137 show that p50-/- mice are more sensitive to total body irradiation-induced lethality than wild-type

138 examined the role of NFkappaB activation in total body irradiation-induced tissue damage.

139 Exposure of mice to total body irradiation induces nuclear factor kappaB (NF

140 g from the combined effects of cyclosporine, total body irradiation, infections, high-dose chemothera

141 reert2)/Met(+/+)/LacZ) were exposed to 10 Gy total body irradiation; intestinal tissues were collecte

142 Total body irradiation is a component in various host co

143 experimental and clinical scenarios in which total body irradiation is involved.

144 at liver toxicity after cyclophosphamide and total body irradiation is related to cyclophosphamide th

145 approach requires conditioning regimens with total body irradiation, lymphodepleting chemotherapy, an

146 NFkappaB activated by total body irradiation mainly consists of NFkappaB p50/R

147 Upon total body irradiation, medullary complexity was partial

148 D154 (MR1) and rapamycin (Rapa) plus 100 cGy total body irradiation (MR1/Rapa/100 cGy) and transplant

149 were conditioned with cyclophosphamide with total body irradiation (n = 39) or busulfan (n = 1).

150 simulated weightlessness and space-relevant total-body irradiation on vascular responsiveness in mic

151 mice were lymphodepleted by nonmyeloablative total body irradiation or a myeloablative regimen that r

152 e latter treatment, however, did not require total body irradiation or adoptive cell transfer and res

153 there was no difference between receiving a total body irradiation or busulfan based regimens (P = .

154 yclophosphamide associated with fractionated total body irradiation or busulfan.

155 myeloablative regimens, ie, those including total body irradiation or high-dose busulfan.

156 l HCT, where recipients are conditioned with total body irradiation or high-dose chemotherapy.

157 philia A BALB/c mice after reduced-intensity total body irradiation or nonmyeloablative chemotherapy

158 t differences in hazards were observed after total-body irradiation or receipt of an allogeneic versu

159 male sexual function domains declined after total body irradiation (P < .05).

160 m(2) x 5, cyclophosphamide 50 mg/kg, 200 cGy total body irradiation), patients received either matche

161 Patients treated with C-HDT received total body irradiation plus chemotherapy (70%) or chemot

162 h busulfan plus cyclophosphamide and 12 with total body irradiation plus chemotherapy.

163 The patients received 300 cGy of total-body irradiation plus alemtuzumab before transplan

164 iation of conditioning therapy (fractionated total-body irradiation plus high-dose chemotherapy) and

165 sk for osteoporosis and bone fractures after total body irradiation preconditioning.

166 Although nonmyeloblative total body irradiation prevented organ graft rejection,

167 depletion with CD3-immunotoxin, and 100 cGy total body irradiation prior to hematopoietic cell trans

168 A single injection of CBLB502 before lethal total-body irradiation protected mice from both gastroin

169 However total-body irradiation, radiation to the gonads, and che

170 Total body irradiation reduced numbers of proliferating

171 r without T-cell lymphodepletion reduced the total body irradiation requirement to 100 cGy for establ

172 Total body irradiation (RR = 0.6) provided a protective

173 Mice subjected to total body irradiation showed alterations in glucose met

174 or-bearing mice with DMA 2 hours before 8 Gy total body irradiation showed an impressive rescue of ra

175 nti-FVIII immune response, and together with total body irradiation, suppresses anti-FVIII immune res

176 serum at 10 mg at day +10 (single dose), and total-body irradiation t 300 cGy (day 0) before bone-mar

177 Conditioning therapy involved 800 cGy total body irradiation (TBI) (+/- lung shielding to appr

178 s 11.0%, higher among survivors who received total body irradiation (TBI) (17%) than those who did no

179 ence indicates that the addition of low-dose total body irradiation (TBI) (2-4 Gy) to reduced intensi

180 ed: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM,

181 that antithymocyte globulin (ATG) given with total body irradiation (TBI) 200 cGy and fludarabine res

182 re we use bone marrow transplantation (BMT), total body irradiation (TBI) and abdominal irradiation (

183 Lymphodepletion using total body irradiation (TBI) and administering high-dose

184 littermate recipients consisting of 450 cGy total body irradiation (TBI) and anti-CD44 monoclonal an

185 man urine data sets from patients undergoing total body irradiation (TBI) and from a colorectal cance

186 mone (GH) deficiency are complications after total body irradiation (TBI) and hematopoietic cell tran

187 ce were conditioned with decreasing doses of total body irradiation (TBI) and reconstituted with bone

188 ) cell recovery in rhesus macaques following total body irradiation (TBI) and reinfusion of vector-tr

189 BALB/c mice were treated with total body irradiation (TBI) and then infused with C57Bl

190 onmyeloablative chemotherapy with or without total body irradiation (TBI) before adoptive T-cell tran

191 anti-CD45 radioimmunotherapy (RIT) replacing total body irradiation (TBI) before haploidentical HCT i

192 Four dogs received 920 cGy total body irradiation (TBI) before infusion of autologo

193 ost uniformly achieved in dogs given 200 cGy total body irradiation (TBI) before, and a short course

194 Total body irradiation (TBI) can induce lethal myelosupp

195 lantation (BMT), but this procedure requires total body irradiation (TBI) conditioning of the recipie

196 engraftment was only transient with 100 cGy total body irradiation (TBI) conditioning, indicating su

197 at under myeloablative and reduced-intensity total body irradiation (TBI) conditioning, transplantati

198 Total body irradiation (TBI) damages hematopoietic cells

199 eic transplantation with regimens of varying total body irradiation (TBI) doses (0-1575 cGy), with an

200 Total body irradiation (TBI) exposure was associated wit

201 patients with refractory cancer with 100 cGy total body irradiation (TBI) followed by infusion of non

202 equires the recipient mice to undergo lethal total body irradiation (TBI) followed by rescue with who

203 are compared with those of adult mice given total body irradiation (TBI) followed by transplantation

204 BMT, rats were treated with varying doses of total body irradiation (TBI) followed by transplantation

205 not been compared with cyclophosphamide plus total body irradiation (TBI) in adults with advanced ref

206 emission at the time of allo-HSCT and use of total body irradiation (TBI) in patients with non-Hodgki

207 rs of 2 articles have compared busulfan with total body irradiation (TBI) in preparative regimens for

208 Lymphodepletion with total body irradiation (TBI) increases the efficacy of a

209 ood, Shao et al report that a side effect of total body irradiation (TBI) is long-term bone marrow in

210 Fractionated, high-dose total body irradiation (TBI) is used therapeutically to

211 myeloablative conditioning regimens--200 cGy total body irradiation (TBI) or 10 mg/kg busulfan--with

212 (BMT) after conditioning with either lethal total body irradiation (TBI) or an established nonmyeloa

213 in the bone marrow (BM) as a consequence of total body irradiation (TBI) or granulocyte colony-stimu

214 s studies showed that treatment of mice with total body irradiation (TBI) or total lymphoid tissue ir

215 monoclonal antibody before conditioning with total body irradiation (TBI) prevents GVHD but retains G

216 nonmyeloablative chemotherapeutic agents or total body irradiation (TBI) prior to adoptive transfer

217 inhibition using AZ31 prior to 9 or 9.25 Gy total body irradiation (TBI) reduced median time to mori

218 treatment, we determined the minimal dose of total body irradiation (TBI) required when added to anti

219 C57BL/6 mice to a sublethal dose (6.5 Gy) of total body irradiation (TBI) resulted in a sustained qua

220 requency of side effects caused by high-dose total body irradiation (TBI) the nonmyeloablative regime

221 Addition and intensification of total body irradiation (TBI) to the preparative lymphode

222 ) given conventional conditioning, high-dose total body irradiation (TBI) was associated with an incr

223 Total body irradiation (TBI) was associated with develop

224 ft rejection after conditioning with 1 Gy of total body irradiation (TBI) was consistently seen in hi

225 e NSG host environment using preconditioning total body irradiation (TBI) was indispensable for effic

226 ynomolgus monkeys, cyclophosphamide (CP) and total body irradiation (TBI) were compared as part of a

227 l HSCT in which 27 patients conditioned with total body irradiation (TBI) were given a fixed dose of

228 single-exposure, high dose rate (30 cGy/min) total body irradiation (TBI) with cyclophosphamide as co

229 6 transplantation model and ascertained that total body irradiation (TBI) with establishment of chime

230 yeloablative conditioning consisting of 2 Gy total body irradiation (TBI) with or without added fluda

231 of fludarabine, anti-thymocyte globulin, and total body irradiation (TBI) would enable reduction of t

232 al antibodies (mAbs) on Days -6 and -1, 3 Gy total body irradiation (TBI), and 7 Gy thymic irradiatio

233 eived cyclophosphamide (CY), single fraction total body irradiation (TBI), and antithymocyte globulin

234 ns were impaired by a single dose of 200 cGy total body irradiation (TBI), and both GVH and residual

235 ned with antilymphocyte serum (ALS), 100 cGy total body irradiation (TBI), and given 30 x 10(6) allog

236 re treated with cyclophosphamide, etoposide, total body irradiation (TBI), and PBSCT.

237 unrelated donors were rejected after 9.2 Gy total body irradiation (TBI), and that graft resistance

238 ty conditioning (RIC) consisting of low-dose total body irradiation (TBI), cyclophosphamide, and flud

239 is upregulated during lymphopenia induced by total body irradiation (TBI), cyclophosphamide, or Thy1

240 f the endosteal osteoblastic HSC niche after total body irradiation (TBI), defined as relocalization

241 Nonmyeloablative regimens were 2 Gy total body irradiation (TBI), either alone (n = 40) or c

242 ransplantation regimen consisted of low-dose total body irradiation (TBI), preceded in some patients

243 animals were submitted at 60 days to 9.5-Gy total body irradiation (TBI), reconstituted immediately

244 ests that intense immune suppression using a total body irradiation (TBI)-based regimen and hematopoi

245 ive intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in myeloid m

246 outcome when patients had undergone previous total body irradiation (TBI)-containing myeloablative tr

247 second relapse was significantly lower after total body irradiation (TBI)-containing transplant regim

248 way as a new mechanism for the mitigation of total body irradiation (TBI)-induced mortality.

249 isease (GVHD) in recipients conditioned with total body irradiation (TBI).

250 sphamide of 60 mg/kg per day for 2 days, and total body irradiation (TBI).

251 recovery in the blood and bone marrow after total body irradiation (TBI).

252 cy, we developed a murine model of sublethal total body irradiation (TBI).

253 d donors received fludarabine and 200 cGy of total body irradiation (TBI); UCB recipients received cy

254 )) rats were conditioned with 600 to 300 cGy total body irradiation (TBI, day-1), and 100 x 10(6) T-c

255 on, a nonmyeloablative regimen using 200 cGy total-body irradiation (TBI) and mycophenolate mofetil (

256 Next, nine dogs received 4.5 Gy total-body irradiation (TBI) and unmodified marrow graft

257 nsplantation-conditioning regimens including total-body irradiation (TBI) at doses 12 Gy or less did

258 Recipient dogs were given 2-Gy total-body irradiation (TBI) before and a short course o

259 ents, certain other leukemogenic agents, and total-body irradiation (TBI) cause chromosomal damage th

260 tion (SCT) for hematologic malignancies with total-body irradiation (TBI) conditioning regimens, and

261 Impact of total-body irradiation (TBI) in conditioning regimen on

262 to show that temporarily blocking p53 during total-body irradiation (TBI) not only ameliorates acute

263 ars of age, received either cyclophosphamide/total-body irradiation (TBI) or busulfan/cyclophosphamid

264 Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are c

265 ne adults received cyclophosphamide (CY) and total-body irradiation (TBI) supported by autologous bon

266 er 2 (25 patients) or 12 Gy (25 patients) of total-body irradiation (TBI) was administered before cel

267 n diagnosis, type of transplantation, use of total-body irradiation (TBI), and presence of graft-vers

268 with age and after genotoxic stress, such as total-body irradiation (TBI).

269 ool and 100% survival after a lethal dose of total-body irradiation (TBI).

270 d: 4-6 of 6 matched dUCB-TCF (n = 120; TCF = total body irradiation [TBI] 200 cGy + cyclophosphamide

271 ice deficient in both genes survive doses of total-body irradiation that lethally deplete hematopoiet

272 th severe thrombocytopenia induced by 6.5 Gy total body irradiation, thereby markedly abridging the d

273 eted PBSC grafts following conditioning with total body irradiation, thiotepa, and fludarabine.

274 ourteen Cynomolgus monkeys received low dose total body irradiation, thymic irradiation, antithymocyt

275 Furthermore, administering lethal doses of total body irradiation to GF mice produces markedly fewe

276 r synthesis is not detectable in response to total body irradiation unless NaCl is lowered by furosem

277 le protected rodents against lethal doses of total body irradiation up to 13 Gy, whether DIM dosing w

278 de 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamid

279 demia (RR = 3.2, P < .01); conditioning with total body irradiation was associated with an increased

280 Total body irradiation was associated with higher TRM bu

281 A regimen of fludarabine and 200 cGy total body irradiation was followed by infusion of allog

282 Total body irradiation was not required for immunologica

283 In addition, challenge of leukemic mice with total body irradiation was selectively toxic to normal h

284 Total-body irradiation was a major determinant for BCC.

285 Total-body irradiation was a significant risk factor for

286 red on days -21, -20, and -19 and 200 cGy of total-body irradiation was administered on day -1, follo

287 ter they were exposed to increasing doses of total body irradiation, we additionally examined the rol

288 e marrow and to avoid the adverse effects of total body irradiation, we employed a murine parabiosis

289 gh (myeloablative) doses of chemotherapy and total body irradiation, which have been associated with

290 itioned with T-cell depleting antibodies and total body irradiation with or without cyclophosphamide.

291 nrelated donors after conditioning with 2 Gy total body irradiation with or without fludarabine and p

292 three consecutive patients who received 2 Gy total body irradiation with or without fludarabine were

293 Conditioning was with cyclophosphamide and total body irradiation with or without fludarabine.

294 ted with nonmyeloablative conditioning (2 Gy total-body irradiation with [n = 53] or without [n = 11]

295 = 28) donors after conditioning with 2 Gy of total-body irradiation with or without fludarabine.

296 = 85) grafts after conditioning with 2 Gy of total-body irradiation with or without fludarabine.

297 Rats were subjected to 15 Gy of total-body irradiation with x-rays.

298 courses of myeloablative therapy (including total-body irradiation) with PBSCR.

299 ose melphalan and autograft followed by 2-Gy total body irradiation, with or without fludarabine, and

300 e-unit transplantation in patients receiving total body irradiation without antithymocyte globulin (A